

# Giorgio Scagliotti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/788117/publications.pdf>

Version: 2024-02-01

207  
papers

19,320  
citations

38742

50  
h-index

11939

134  
g-index

208  
all docs

208  
docs citations

208  
times ranked

18869  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. <i>Minerva Urology and Nephrology</i> , 2022, 73, .	2.5	4
2	Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100269.	1.1	0
3	Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment. <i>European Journal of Cancer</i> , 2022, 163, 44-54.	2.8	14
4	Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval. <i>Journal of Bone Oncology</i> , 2022, 33, 100416.	2.4	21
5	Prognostic factors in metastatic castration resistant prostate cancer patients treated with Radium-223: a retrospective study. <i>Minerva Urology and Nephrology</i> , 2022, , .	2.5	2
6	Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside. <i>Cells</i> , 2022, 11, 803.	4.1	19
7	SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 75.	8.6	7
8	International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2022, , .	1.1	4
9	TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm) – Exploration of germline DDR alteration landscape and potential associations with antitumor activity.. <i>Journal of Clinical Oncology</i> , 2022, 40, 157-157.	1.6	2
10	Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis. <i>Tumori</i> , 2022, , 030089162210771.	1.1	1
11	COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery. <i>Biomedicines</i> , 2022, 10, 776.	3.2	8
12	A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103639.	4.4	13
13	Antiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. <i>European Journal of Cancer</i> , 2022, 166, 112-125.	2.8	4
14	New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103682.	4.4	5
15	Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, , 1.	2.8	1
16	Molecular Subtypes of Extra-pulmonary Neuroendocrine Carcinomas Identified by the Expression of Neuroendocrine Lineage-Specific Transcription Factors. <i>Endocrine Pathology</i> , 2022, 33, 388-399.	9.0	7
17	Molecular testing and patterns of treatment in patients with NSCLC: An IASLC analysis of ASCO CancerLinQ Discovery Data.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9128-9128.	1.6	1
18	Abstract CT031: TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm) – Exploration of genomic loss of heterozygosity (gLOH) and potential associations with antitumor activity. <i>Cancer Research</i> , 2022, 82, CT031-CT031.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Diagnostics of BAP1-Tumor Predisposition Syndrome by a Multitest Approach: A Ten-Year-Long Experience. <i>Diagnostics</i> , 2022, 12, 1710.	2.6	4
20	Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103185.	4.4	41
21	A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design. <i>Clinical Lung Cancer</i> , 2021, 22, e63-e66.	2.6	22
22	Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 812-825.	3.9	5
23	Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma. <i>Cancers</i> , 2021, 13, 2564.	3.7	16
24	Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma. <i>Cancers</i> , 2021, 13, 2332.	3.7	4
25	Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations. <i>Cancers</i> , 2021, 13, 2425.	3.7	7
26	Talazoparib (TALA), an oral poly (ADP-ribose) polymerase (PARP) inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR) alterations: Detailed safety analyses from TALAPRO-1 trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 5047-5047.	1.6	1
27	Abstract CT027: TALAPRO-1 final data: Talazoparib (TALA) monotherapy in men with DNA damage response alterations (DDRalt) and metastatic castration-resistant prostate cancer (mCRPC): Exploration of DDRalt germline/somatic origin and zygosity. , 2021, , .		0
28	DNA Methylation Profiling Discriminates between Malignant Pleural Mesothelioma and Neoplastic or Reactive Histologic Mimics. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 834-846.	2.8	7
29	Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC. <i>Endocrine-Related Cancer</i> , 2021, 28, R207-R216.	3.1	14
30	Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3679-3692.	4.2	15
31	Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1250-1264.	10.7	159
32	Repositioning PARP inhibitors in the treatment of thoracic malignancies. <i>Cancer Treatment Reviews</i> , 2021, 99, 102256.	7.7	7
33	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1647-1662.	1.1	274
34	MA12.07 Oncological Procedures and Risk Assessment of COVID-19 in Thoracic Cancer Patients: A Picture From an Italian Cancer Center. <i>Journal of Thoracic Oncology</i> , 2021, 16, S923-S924.	1.1	1
35	Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report. <i>Tumori</i> , 2021, 107, NP149-NP154.	1.1	4
36	Humoral immune response to SARS-CoV-2 in five different groups of individuals at different environmental and professional risk of infection. <i>Scientific Reports</i> , 2021, 11, 24503.	3.3	6

#	ARTICLE	IF	CITATIONS
37	Wnt/IL-1 $\beta$ /IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5. <i>International Journal of Cancer</i> , 2020, 146, 192-207.	5.1	29
38	Long-term disease control in a metastatic squamous cell carcinoma of the oral cavity treated with maintenance metronomic capecitabine. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 240-243.	0.9	3
39	Carcinoid heart failure in a duodenal neuroendocrine tumor: role of cardiac surgery in a challenging patient and brief review of the literature. <i>Acta Oncologica</i> , 2020, 59, 315-319.	1.8	0
40	Multiple Assays to Determine Methylguanine-Methyltransferase Status in Lung Carcinoids and Correlation with Clinical and Pathological Features. <i>Neuroendocrinology</i> , 2020, 110, 1-9.	2.5	2
41	A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2020, 15, 80-90.	1.1	55
42	Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018. <i>Lung Cancer</i> , 2020, 139, 47-54.	2.0	28
43	Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 609-617.	1.1	27
44	Discrepancy between tumor response and hematologic response in a patient with thymoma and aplastic anemia treated with ciclosporin. <i>Mediastinum</i> , 2020, 4, 8-8.	1.1	0
45	Neuroendocrine breast carcinoma: a rare but challenging entity. <i>Medical Oncology</i> , 2020, 37, 70.	2.5	27
46	Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1119-1136.	1.1	82
47	What does the future hold for the Lung Cancer Ambition Alliance project: an interview with Giorgio Scagliotti. <i>Future Oncology</i> , 2020, 16, 221-223.	2.4	0
48	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 914-947.	1.1	119
49	Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe. <i>Cancers</i> , 2020, 12, 1672.	3.7	50
50	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. <i>Journal of Thoracic Oncology</i> , 2020, 15, 709-740.	1.1	205
51	Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 146, 102877.	4.4	14
52	Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. <i>ESMO Open</i> , 2020, 5, e000567.	4.5	7
53	Double immune checkpoint blockade in advanced NSCLC. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102980.	4.4	12
54	Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102994.	4.4	13

#	ARTICLE	IF	CITATIONS
55	The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1434-1448.	1.1	107
56	Systemic recurrence of endometrial cancer more than 10 years after hysterectomy: a report of two cases and a brief review of the literature. <i>Journal of the Egyptian National Cancer Institute</i> , 2020, 32, 41.	1.5	6
57	Prolonged Adrenal Insufficiency After the Discontinuation of Mitotane Therapy. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2020, 20, 485-487.	1.2	7
58	Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 737-745.	3.9	6
59	Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won. <i>Translational Lung Cancer Research</i> , 2020, 9, 2545-2556.	2.8	13
60	Ocular metastases from neuroendocrine tumors: A literature review. <i>Seminars in Oncology</i> , 2020, 47, 144-147.	2.2	6
61	Patients With Lung Cancer and Coronavirus Disease 2019 Epidemic: An Experience From an Italian University Hospital. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100067.	1.1	2
62	Long-term disease control and high clinical benefit in a patient with advanced thyroid cancer treated with lenvatinib. <i>Future Oncology</i> , 2019, 15, 3-6.	2.4	3
63	Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 332-347.e2.	1.9	9
64	Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma. <i>Seminars in Oncology</i> , 2019, 46, 145-154.	2.2	14
65	Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naïve patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 569-580.	10.7	117
66	Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Consensus Report. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2109-2119.	1.1	189
67	First-line immune-chemotherapy combination: the right strategy to fight squamous non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, 546-549.	2.8	3
68	The Circadian Rhythm of Breakthrough Pain Episodes in Terminally-ill Cancer Patients. <i>Cancers</i> , 2019, 11, 18.	3.7	13
69	Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1458-1471.	1.1	41
70	Spread through air spaces (STAS) is a predictor of poor outcome in atypical carcinoids of the lung. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 325-334.	2.8	18
71	Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents. <i>Endocrine</i> , 2019, 64, 724-726.	2.3	5
72	Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, e251-e259.	3.7	11

#	ARTICLE	IF	CITATIONS
73	Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. <i>Nature Biotechnology</i> , 2019, 37, 55-63.	17.5	203
74	Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. <i>Cancer Treatment Reviews</i> , 2019, 74, 35-42.	7.7	30
75	Quality-of-life (QoL) assessment and reporting in prostate cancer: A systematic review of phase III trials published between 2012 and 2016.. <i>Journal of Clinical Oncology</i> , 2019, 37, 219-219.	1.6	3
76	Capecitabine plus temozolomide in well- or moderately-differentiated primary atypical neuroendocrine tumours " single-centre experience of two cases. <i>Endokrynologia Polska</i> , 2019, 70, 380-383.	1.0	3
77	Inhibition of Tumor Angiogenesis in the Treatment of Lung Cancer. , 2019, , 497-511.		0
78	Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy. <i>Clinical Lung Cancer</i> , 2018, 19, 377-386.	2.6	0
79	Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study. <i>Journal of Thoracic Oncology</i> , 2018, 13, 849-854.	1.1	39
80	Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?. <i>Future Oncology</i> , 2018, 14, 1223-1231.	2.4	8
81	Loss of C/EBP- $\beta$ LIP drives cisplatin resistance in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2018, 120, 34-45.	2.0	25
82	Detailed genomic characterization identifies high heterogeneity and histotype-specific genomic profiles in adrenocortical carcinomas. <i>Modern Pathology</i> , 2018, 31, 1257-1269.	5.5	17
83	MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression. <i>International Journal of Clinical Oncology</i> , 2018, 23, 281-286.	2.2	1
84	Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, R1-R9.	3.1	13
85	Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 124-133.	1.1	52
86	Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. <i>Oncolmmunology</i> , 2018, 7, e1398874.	4.6	41
87	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1818-1831.	1.1	133
88	Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7353-7368.	2.0	58
89	Hormonal treatment and quality of life of prostate cancer patients: new evidence. <i>Minerva Urology and Nephrology</i> , 2018, 70, 144-151.	2.5	25
90	Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in <i>BAP1</i> or other DNA repair genes. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 573-583.	2.8	43

#	ARTICLE	IF	CITATIONS
91	Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from theÂIASLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1248-1268.	1.1	515
92	Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. <i>Cancer Treatment Reviews</i> , 2018, 69, 215-223.	7.7	19
93	FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: a case report. <i>BMC Cancer</i> , 2018, 18, 470.	2.6	0
94	Pemetrexed, Vitamin B12, and Thoracic Tumors: The Times, They Are A-Changinâ€™. <i>Clinical Lung Cancer</i> , 2018, 19, 461-463.	2.6	2
95	Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 318-324.	1.9	4
96	High miR-100 expression is associated with aggressive features and modulates TORC1 complex activation in lung carcinoids. <i>Oncotarget</i> , 2018, 9, 27535-27546.	1.8	5
97	Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8568-8568.	1.6	0
98	Biases in assessment and reporting of health-related quality of life (QoL): A systematic review of oncology randomized phase III trials published between 2012 and 2016.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18719-e18719.	1.6	0
99	Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8566-8566.	1.6	0
100	Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practiceâ€™A new approach to improve personalized translational research. <i>Lung Cancer</i> , 2017, 107, 84-90.	2.0	30
101	Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel. <i>Acta OncolA³gica</i> , 2017, 56, 555-562.	1.8	24
102	Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer. <i>Cancer Treatment Reviews</i> , 2017, 54, 1-9.	7.7	44
103	Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma. <i>Endocrine Pathology</i> , 2017, 28, 95-102.	9.0	15
104	Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit. <i>Clinical Colorectal Cancer</i> , 2017, 16, 372-376.	2.3	19
105	Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies. <i>Clinical Lung Cancer</i> , 2017, 18, 489-496.	2.6	14
106	LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. <i>Clinical Lung Cancer</i> , 2017, 18, 589-593.	2.6	17
107	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1183-1209.	1.1	40
108	Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 104, 45-51.	2.0	9

#	ARTICLE	IF	CITATIONS
109	Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?. <i>Cancer Treatment Reviews</i> , 2017, 61, 70-81.	7.7	62
110	Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1654-1663.	1.1	81
111	Implementation of precision medicine in clinical trials in thoracic oncology: Which are the hurdles?. <i>Cancer</i> , 2017, 123, 4764-4766.	4.1	0
112	Lung cancer: current therapies and new targeted treatments. <i>Lancet, The</i> , 2017, 389, 299-311.	13.7	2,267
113	An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 383-389.	1.1	18
114	MA 19.03 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1884.	1.1	3
115	Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. <i>BioMed Research International</i> , 2017, 2017, 1-13.	1.9	10
116	Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8506-8506.	1.6	1
117	Inhibition of Tumor Angiogenesis in the Treatment of Lung Cancer. , 2017, , 1-15.		1
118	Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2016, 27, 1612-1619.	1.2	30
119	The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 104, 9-20.	4.4	87
120	BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2006-2017.	1.1	83
121	Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1053-1062.	2.4	14
122	A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy. <i>Lung Cancer</i> , 2016, 100, 20-23.	2.0	10
123	Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. <i>Lung Cancer</i> , 2016, 100, 30-37.	2.0	3
124	Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With <i>ALK</i> -Rearranged Non-“Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 2866-2873.	1.6	316
125	Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy. <i>Radiologia Medica</i> , 2016, 121, 950-957.	7.7	3
126	Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. <i>Investigational New Drugs</i> , 2016, 34, 625-635.	2.6	52



#	ARTICLE	IF	CITATIONS
127	Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2016, 11, 504-515.	1.1	19
128	Scientific Advances in Lung Cancer 2015. <i>Journal of Thoracic Oncology</i> , 2016, 11, 613-638.	1.1	231
129	Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2016, 44, 61-73.	7.7	56
130	Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 69, 563-573.	1.9	101
131	Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS8574-TPS8574.	1.6	2
132	Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines. <i>Oncotarget</i> , 2016, 7, 76577-76589.	1.8	13
133	Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer. <i>Oncotarget</i> , 2016, 7, 14394-14404.	1.8	23
134	Bioequivalence of Branded and Generic Oxaliplatin: From Preclinical Assessment to Clinical Incidence of Hypersensitivity Reactions. <i>Anticancer Research</i> , 2016, 36, 5163-5170.	1.1	3
135	Raising the bar for enthusiasm when looking at results of randomized phase II trials-the case of sunitinib in small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 89-91.	2.8	1
136	Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker. <i>Clinical Lung Cancer</i> , 2015, 16, 348-357.	2.6	14
137	Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2667-2674.	1.6	237
138	Papillary renal cell carcinoma: A review of the current therapeutic landscape. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 100-112.	4.4	104
139	Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study. <i>Journal of Thoracic Oncology</i> , 2015, 10, 492-499.	1.1	142
140	Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 consultation cases. <i>Human Pathology</i> , 2015, 46, 1799-1807.	2.0	44
141	Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 884-892.	7.7	141
142	Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. <i>Oncotarget</i> , 2015, 6, 12520-12528.	1.8	47
143	Association between levels of hormones implied in steroid biosynthesis pathway and activity of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): An exploratory analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16066-e16066.	1.6	0
144	The lesson learned from figitumumab clinical program and the hope for better results in squamous lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 15-7.	2.8	2

#	ARTICLE	IF	CITATIONS
145	CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome. <i>Oncotarget</i> , 2014, 5, 6191-6205.	1.8	13
146	Squamous carcinoma of the lung: still a long and winding road to successful treatment. <i>Lung Cancer Management</i> , 2014, 3, 365-368.	1.5	0
147	A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2014, 25, 2156-2162.	1.2	26
148	Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials. <i>Lung Cancer</i> , 2014, 85, 408-414.	2.0	19
149	Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. <i>Human Pathology</i> , 2014, 45, 665-673.	2.0	27
150	MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations. <i>Human Pathology</i> , 2014, 45, 1555-1562.	2.0	50
151	Tumor/Stromal Caveolin-1 Expression Patterns in Pleural Mesothelioma Define a Subgroup of the Epithelial Histotype With Poorer Prognosis. <i>American Journal of Clinical Pathology</i> , 2014, 141, 816-827.	0.7	9
152	Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS7612-TPS7612.	1.6	1
153	Histologic and genotypic re-evaluation of non-small cell lung cancer (NSCLC): A monocentric study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19083-e19083.	1.6	0
154	Next-generation sequencing in malignant pleural mesothelioma: A retrospective study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7530-7530.	1.6	0
155	Differential thymidylate synthase expression in lung cancer adenocarcinoma subtypes.. <i>Journal of Clinical Oncology</i> , 2014, 32, e18539-e18539.	1.6	0
156	Meta-analysis examining impact of age on pemetrexed (pem) efficacy for the treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2014, 32, e19040-e19040.	1.6	1
157	Second Italian Consensus Conference on Malignant Pleural Mesothelioma: State of the art and recommendations. <i>Cancer Treatment Reviews</i> , 2013, 39, 328-339.	7.7	51
158	The emerging role of MET/HGF inhibitors in oncology. <i>Cancer Treatment Reviews</i> , 2013, 39, 793-801.	7.7	182
159	An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1529-1537.	1.1	33
160	Current State-of-the-Art Therapy for Advanced Squamous Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 354-358.	3.8	9
161	Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures. <i>Translational Lung Cancer Research</i> , 2013, 2, 372-81.	2.8	44
162	Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2070-2078.	1.6	205

#	ARTICLE	IF	CITATIONS
163	Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 172-178.	1.6	223
164	International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer: MONET1. <i>Journal of Clinical Oncology</i> , 2012, 30, 2829-2836.	1.6	179
165	Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Nonâ€“Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3640-3647.	1.6	166
166	The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. <i>Cancer Treatment Reviews</i> , 2012, 38, 292-302.	7.7	88
167	ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development. <i>European Journal of Cancer</i> , 2012, 48, 961-973.	2.8	84
168	Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Nonâ€“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2012, 13, 391-395.	2.6	128
169	Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fineâ€“needle aspiration cytology. <i>Cancer</i> , 2011, 117, 3416-3423.	4.1	124
170	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2011, 6, 244-285.	1.1	4,127
171	Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 64-70.	1.1	236
172	Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1835-1842.	1.6	421
173	Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2010, 15, 436-446.	3.7	54
174	A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2010, 68, 420-426.	2.0	55
175	The Role of Histology with Common First-line Regimens for Advanced Non-small Cell Lung Cancer: A Brief Report of the Retrospective Analysis of a Three-arm Randomized Trial. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1568-1571.	1.1	44
176	Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemo-naïve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study. <i>European Journal of Cancer</i> , 2009, 45, 2298-2303.	2.8	47
177	The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies. <i>Oncologist</i> , 2009, 14, 253-263.	3.7	669
178	Nonsmall cell lung cancer in never smokers. <i>Current Opinion in Oncology</i> , 2009, 21, 99-104.	2.4	69
179	Targeted therapies in bronchioloalveolar carcinoma. <i>Targeted Oncology</i> , 2008, 3, 197-204.	3.6	1
180	Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naïve Patients With Advanced-Stage Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 3543-3551.	1.6	3,032

#	ARTICLE	IF	CITATIONS
181	Optimizing Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, S86-S91.	1.1	17
182	Multimodality approach to early-stage non-small cell lung cancer. <i>Lung Cancer</i> , 2007, 57, S6-S11.	2.0	10
183	Emerging drugs for mesothelioma. <i>Expert Opinion on Emerging Drugs</i> , 2007, 12, 127-137.	2.4	10
184	Advances in diagnosis and treatment of malignant pleural mesothelioma. <i>Oncology Reviews</i> , 2007, 1, 91-102.	1.8	2
185	Antimetabolites and cancer: emerging data with a focus on antifolates. <i>Expert Opinion on Therapeutic Patents</i> , 2006, 16, 189-200.	5.0	14
186	Proteasome inhibitors in lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 58, 177-189.	4.4	57
187	The Way Forward: New Drugs and New Therapeutic Strategies in Lung Cancer Therapy. <i>Clinical Lung Cancer</i> , 2006, 7, S109-S110.	2.6	0
188	Pemetrexed plus carboplatin or oxaliplatin in advanced non-small cell lung cancer. <i>Seminars in Oncology</i> , 2005, 32, S5-S8.	2.2	10
189	The ALPI Trial: The Italian/European Experience with Adjuvant Chemotherapy in Resectable Non-Small Lung Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5011s-5016s.	7.0	58
190	An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2855-2866.	1.8	8
191	Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. <i>Clinical Cancer Research</i> , 2005, 11, 690-6.	7.0	97
192	Current Development of Adjuvant Treatment of Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2004, 6, S63-S70.	2.6	4
193	Docetaxel in combined-modality treatment of inoperable locally or regionally advanced lung cancer. <i>Lung Cancer</i> , 2004, 46, S13-S21.	2.0	5
194	The Biology of Epidermal Growth Factor Receptor in Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 4227s-4232s.	7.0	219
195	Gefitinib (ZD1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2004, 22, 7081-7081.	1.6	12
196	Pemetrexed in front-line chemotherapy for advanced non-small-cell lung cancer. <i>Oncology</i> , 2004, 18, 32-7.	0.5	1
197	Adjuvant therapy in completely resected non-small-cell lung cancer. <i>Current Oncology Reports</i> , 2003, 5, 318-325.	4.0	19
198	Efficacy of neoadjuvant strategies with gemcitabine and other chemotherapy in resectable non-small cell lung cancer: a combined modality approach. <i>Seminars in Oncology</i> , 2003, 30, 13-18.	2.2	0

#	ARTICLE	IF	CITATIONS
199	Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1453-1461.	6.3	550
200	Adjuvant chemotherapy after complete resection for early stage NSCLC. <i>Lung Cancer</i> , 2003, 42, 47-51.	2.0	13
201	Pemetrexed and its emerging role in the treatment of thoracic malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 853-863.	4.1	5
202	Docetaxel-Based Combined-Modality Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2003, 8, 361-374.	3.7	12
203	Gemcitabine (Gemzar®)-based induction chemotherapy in non-small-cell lung cancer. <i>Lung Cancer</i> , 2002, 38, 13-19.	2.0	5
204	Tyrosine kinase signal transduction inhibitors. <i>Clinical trials. I Supplementi Di Tumori</i> , 2002, 1, S34-6.	0.1	0
205	Challenging the platinum combinations: Docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer. <i>Seminars in Oncology</i> , 2001, 28 Suppl 2, 15-21.	2.2	0
206	Gemcitabine as Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 1999, 17, 2081-2081.	1.6	158
207	Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 481-489.	0.8	0